NeoGenomics NEO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| NET REVENUE by Product | ||||||
| Client direct billing | $131.61M-1.3% | $133.36M+0.8% | $132.29M+0.9% | $131.16M+7.5% | $122.04M-1.0% | |
| Commercial insurance | $30.94M-1.5% | $31.42M-3.2% | $32.47M+12.9% | $28.77M+15.7% | $24.86M-7.0% | |
| Medicare and other government | $24.15M-5.0% | $25.4M+10.6% | $22.97M+7.4% | $21.39M+1.4% | $21.1M-2.9% | |
| Self-pay | -$17K— | —— | $69K+245% | $20K-48.7% | $39K-82.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does NeoGenomics break its business down?
- NeoGenomics (NEO) reports net revenue by product across 4 parts — Client direct billing, Commercial insurance, Medicare and other government and Self-pay. Each is extracted from the segment footnotes and tracked over time.
- Where does NeoGenomics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in NeoGenomics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
